Company intelligence
Biolexis Therapeutics, Inc.
Accelerating Drug Discovery
Biotechnology Research
Lehi, US
16 employees
Founded 2021
2 public signals
About Biolexis Therapeutics, Inc.
Next-generation metabolic medicine, one pill at at time. Biolexis is developing best-in-class oral GLP-1 receptor agonists and complementary AMPK activators designed to deliver injectable-level efficacy with superior tolerability--engineered from day one for convenient daily dosing and fixed-dose combinations.
Verified activity
Signals from Biolexis Therapeutics, Inc.
2 published signals
Research & Knowledge
Biolexis Therapeutics, Inc. reported that in preclinical models, the combination BLX-0871 retained 87% of lean mass.
Reported by Biolexis Therapeutics, Inc.
Products & Services
Biolexis Therapeutics, Inc. is building BLX-7006, an oral, small-molecule GLP-1 receptor agonist that does not require a cold chain, no injection supply chain, and no fasting requirement.
Reported by Biolexis Therapeutics, Inc.